Venaxis, Inc. (APPY)
-NasdaqCM 1.32 
0.05(3.94%) Jun 18, 4:00PM EDT|After Hours
:
1.31 0.01 (0.76%) Jun 18, 5:08PM EDT
| Prev Close: | 1.27 |
|---|
| Open: | 1.27 |
|---|
| Bid: | 1.27 x 1000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.50 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.26 - 1.34 |
|---|
| 52wk Range: | 1.15 - 3.18 |
|---|
| Volume: | 564,551 |
|---|
| Avg Vol (3m): | 605,669 |
|---|
| Market Cap: | 26.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.42 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Venaxis, Inc: A Long-Term Investment With Potential For Substantial Gainsat Seeking Alpha(Tue, Jun 18)
- VENAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or BylawsEDGAR Online(Thu, Jun 13)
- JAMA Pediatrics Study Highlights Cancer Risk Associated with CT ScansPR Newswire(Thu, Jun 13)
- Canaccord Genuity Sees Strong Upside In Venaxis' Shares And Set A $7 Price Targetat Seeking Alpha(Thu, Jun 6)
- VENAXIS, INC. FinancialsEDGAR Online Financials(Tue, Jun 4)
- VENAXIS, INC. FinancialsEDGAR Online Financials(Sat, Jun 1)
- 3 Stocks Under $10 Making Big Movesat TheStreet(Fri, May 31)
- Venaxis Closes Underwritten Public Offering, Including Full Over-AllotmentPR Newswire(Thu, May 30)
- VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, May 30)
- 4 Healthcare Stock Stories For the Holiday Weekendat Wall St. Cheat Sheet(Fri, May 24)
- BRIEF-Venaxis prices 10 million shares at $1.25 per shareat Reuters(Fri, May 24)
- VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements andEDGAR Online(Thu, May 23)
- Venaxis Announces Pricing of Offering of Common Stock and WarrantsPR Newswire(Thu, May 23)
- VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial ObligatiEDGAR Online(Thu, May 9)
- VENAXIS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 739.23 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.10 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.33 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.09 |
|---|
Business Summary
Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The companys research and development activities primarily focus on a human acute appendicitis blood-based test.
View More